Clinical Trial Update: SILtuximab in Viral ARds (SILVAR) Study [Phase 3]

View source ↗

Summary

Phase 3 trial of SILtuximab in viral ARDS (SILVAR) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Diseases
• Pneumonia
• Respiratory Distress Syndrome
• Respiratory Tract Disease
• Respiratory Tract Infections

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: RECORDATI GROUP | Conditions: Acute Respiratory Distress Syndrome, Lung Diseases | Phase 3 | Status: TERMINATED